Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H27N3O4 |
Molecular Weight | 409.4782 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(C=CC=C3)N(C)C1=O
InChI
InChIKey=JURYTIUJMYPBNN-GKCIPKSASA-N
InChI=1S/C23H27N3O4/c1-13(2)20(27)22(29)24-14(3)21(28)25-19-17-11-6-5-9-15(17)16-10-7-8-12-18(16)26(4)23(19)30/h5-14,19-20,27H,1-4H3,(H,24,29)(H,25,28)/t14-,19-,20-/m0/s1
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57327010
Created by
admin on Sat Dec 16 14:58:29 GMT 2023 , Edited by admin on Sat Dec 16 14:58:29 GMT 2023
|
PRIMARY | |||
|
LY 900009
Created by
admin on Sat Dec 16 14:58:29 GMT 2023 , Edited by admin on Sat Dec 16 14:58:29 GMT 2023
|
PRIMARY | MedKoo CAT NO.: 206715, CAS NO.: 209984-68-9Description: LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the .GAMMA.-secretase protein. LY900009 inhibited plasma levels of amyloid-.BETA. peptide in a dose-dependent manner with 80-90% inhibition observed in the 30- to 60-mg cohorts. LY900009 is an orally available GSI (A.BETA.: IC50= 10.912.1 nMNotch: IC50 = 14.1 nM) that was developed as a candidate therapeutic drug against AD (IDENTITY trial), which failed in phase III trials. (last updated: 4/18/2016). | ||
|
LY-900009
Created by
admin on Sat Dec 16 14:58:29 GMT 2023 , Edited by admin on Sat Dec 16 14:58:29 GMT 2023
|
PRIMARY | LY-900009 is a selective small-molecule inhibitor of .GAMMA.-secretase with IC50 value of 0.27nM.Notch signaling plays a critical role in stem cell function and is deragulated in different forms of cancer. .GAMMA.-secretase cleaves Notch receptor and regulates its signaling. LY-900009 is an oral notch inhibitor for the treatment of cancer but is now terminated in Phase I.The phase I study shows that LY900009 causes adverse events including diarrhea, vomiting, nausea, fatigue, anorexia, hypophosphatemia and rash at different grades. Treatment of 60mg LY900009 shows dose-limiting toxicities of fatigue and diarrhea respectively in 2 patients. The maximum tolerated dose (MTD) of LY900009 is identified at 30mg. And the elimination half-life is about 2-3 hrs. As a .GAMMA.-secretase inhibitor, LY900009 also decreases plasma levels of amyloid-.BETA. in a dose-dependent manner. | ||
|
DTXSID701102553
Created by
admin on Sat Dec 16 14:58:29 GMT 2023 , Edited by admin on Sat Dec 16 14:58:29 GMT 2023
|
PRIMARY | |||
|
PX8XQ3H3RV
Created by
admin on Sat Dec 16 14:58:29 GMT 2023 , Edited by admin on Sat Dec 16 14:58:29 GMT 2023
|
PRIMARY | |||
|
209984-68-9
Created by
admin on Sat Dec 16 14:58:29 GMT 2023 , Edited by admin on Sat Dec 16 14:58:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY